InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: dangerM post# 44140

Friday, 04/13/2018 10:25:00 PM

Friday, April 13, 2018 10:25:00 PM

Post# of 48316
From this statement in the abstract I believe Oncosec will have more than 5 patient data to report. More than 2 patients treated with Opdivo after ep-il12 will be a major plus if we see a few more responders to combo therapy. Since the abstract submission they would have had enough time to dose a few more patients in my opinion.

"At the time of abstract submission, 5 patients have completed all study-related procedures ... Two patients with treatment refractory TNBC received nivolumab ... and experienced clinically meaningful objective responses. Updated data will be presented."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News